Press Releases

  FEBRUARY 22, 2010
09:45 AM NEW STORY CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression Of Rheumatoid Arthritis

  FEBRUARY 17, 2010
09:00 AM NEW STORY CEL-SCI Corporation Releases Letter To Shareholders

  FEBRUARY 16, 2010
09:00 AM NEW STORY CEL-SCI Corporation Reports First Quarter 2010 Financial Results

  FEBRUARY 3, 2010
09:00 AM NEW STORY CEL-SCI To Present At 12TH Annual BIO CEO & Investor Conference

  JANUARY 15, 2010
09:35 AM NEW STORY CEL-SCI Hires Vice President Of Manufacturing/Facilities And Commercial Operations

  JANUARY 13, 2010
04:20 PM NEW STORY CEL-SCI Corporation Announces 2009 Financial Results

  JANUARY 11, 2010
09:30 AM NEW STORY CEL-SCI Completes Validation Of Manufacturing Facility Allowing It To Commence Manufacturing Of Multikine

  DECEMBER 1, 2009
10:15 AM CEL-SCI Retains Global Contract Research Organization To Manage Upcoming Phase III Clinical Trial For Its Cancer Drug Multikine

  NOVEMBER 18, 2009
09:45 AM CEL-SCI Announces Start Of First Clinical Study Of Investigational LEAPS-H1N1 Treatment For Hospitalized H1N1 Infected Patients At Johns Hopkins University School Of Medicine

  NOVEMBER 9, 2009
09:40 AM CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability To Modify Immune Response

  NOVEMBER 6, 2009
09:45 AM CEL-SCI To Conduct First Clinical Study Of Investigational LEAPS-H1N1 Treatment For Hospitalized H1N1 Infected Patients At Johns Hopkins University School Of Medicine

  OCTOBER 26, 2009
09:55 AM CEL-SCI Corporation Strengthens Balance Sheet Through Receipt Of $10 Million From Warrant Exercises

  OCTOBER 19, 2009
09:45 AM CEL-SCI Presents Data At American College Of Rheumatology Conference Which Suggests That CEL-2000 Has Potential To Slow Damage Caused By Rheumatoid Arthritis

  OCTOBER 5, 2009
02:30 PM CEL-SCI Corporation Releases Letter to Shareholders

  SEPTEMBER 23, 2009
10:16 AM CEL-SCI Hires Clinical Research Organization For Clinical Study With Hospitalized H1N1-Infected Patients

  SEPTEMBER 16, 2009
1:10 PM CEL-SCI Corporation To Raise $20 Million In Registered Direct Offering

  SEPTEMBER 16, 2009
07:30 AM CEL-SCI To Commence First Clinical Study With Hospitalized H1N1 Infected Patients

  SEPTEMBER 02, 2009
09:00 AM CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes

  AUGUST 20, 2009
09:15 AM CEL-SCI Signs Definitive Agreement To Raise $4.4 Million In Registered Direct Offering

  AUGUST 18, 2009
10:09 AM CEL-SCI Expands H1N1 Flu Virus Work

  AUGUST 14, 2009
04:25 PM CEL-SCI Corporation Reports Third Quarter 2009 Financial Results

  July 10, 2009
08:30 AM CEL-SCI to Present Data From Multikine Clinical Trials at National Institutes Of Health (NIH), National Cancer Institute (NCI) Seminar Series

  July 7, 2009
09:45 AM CEL-SCI Corporation Releases Letter to Shareholders

  June 24, 2009
09:25 AM CEL-SCI Files Patent Application to Support Company’s Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

  June 24, 2009
09:20 AM CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering

  June 16, 2009
09:00 AM CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process that Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference

  June 9, 2009
09:35 AM CEL-SCI Expands Testing of its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses

  June 5, 2009
08:59 AM CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

  May 26, 2009
09:00 AM CEL-SCI Developing Immune-Based Treatment Against Swine And Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S Technology

  May 15, 2009
03:49 PM CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results

  April 28, 2009
09:37 ET CEL-SCI’s L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

  April 27, 2009
10:00 ET CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating that its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

  April 14, 2009
14:09 ET CEL-SCI Corporation Releases Letter to Shareholders

  March 10, 2009
08:30 ET CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and other Biological Products

  March 9, 2009
09:30 ET CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine® for Republic of South Africa

  February 20, 2009
08:55 ET CEL-SCI Corporation Releases Letter to Shareholders

  January 07, 2009
09:35 ET CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine

  December 12, 2008
10:11 ET CEL-SCI Corporation Releases Letter to Shareholders

  December 3, 2008
09:45 ET Updated Pictures of CEL-SCI Manufacturing Facility Available Online

  November 14, 2008
10:00 ET New Data Points To Long Lasting Beneficial Effects Of CEL-SCI’s Rheumatoid Arthritis Vaccine

  November 3, 2008
09:45 ET CEL-SCI Announces Expansion Of Exclusive Licensing Agreement For Cancer Drug Multikine

  October 09, 2008
09:40 ET CEL-SCI Takes Delivery Of New Manufacturing Facility

  October 07, 2008
09:40 ET CEL-SCI Enters Agreement With National Institutes Of Health Clinical Center To Determine The Molecular Basis Of Multikine Anti-Tumor Effect

  September 16, 2008
09:40 ET CEL-SCI Expects To Take Delivery Of New Manufacturing Facility On October 8, 2008

  September 5, 2008
09:45 ET DATA SUGGEST CEL-SCI’S CEL-2000 VACCINE PREVENTS OR RETARDS PERMANENT DAMAGE OF RHEUMATOID ARTHRITIS

  August 20 , 2008
10:40 ET CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS

  August 20 , 2008
09:15 ET

CEL-SCI CORPORATION REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS

  August 19 , 2008
11:00 ET CEL-SCI ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH TEVA FOR CANCER DRUG MULTIKINE

  June 17 , 2008
10:00 ET CEL-SCI ANNOUNCES DISCOVERY OF NOVEL COMPOUND FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

  June 9 , 2008
10:00 ET CEL-SCI PRESENTS FAVORABLE DATA FOR LEAPS VACCINE TECHNOLOGY AT PRESTIGIOUS IMMUNOLOGY CONFERENCE

  June 4 , 2008
10:00 ET CEL-SCI CORPORATION Manufacturing Facility For Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter

  May 16 , 2008
10:00 ET CEL-SCI CORPORATION Reports Second Quarter 2008 Financial Results

  Mar 03 , 2008
09:45 ET CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility For Pivotal Phase III Cancer Trial

  Feb 14 , 2008
09:45 ET CEL-SCI CORPORATION REPORTS FIRST QUARTER FINANCIAL RESULTS

  Jan 28 , 2008
09:45 ET CEL-SCI Corporation Releases Letter to Shareholders

  JAN 14 , 2008
09:15 ET CEL-SCI CORPORATION ANNOUNCES 2007 FINANCIAL RESULTS

  Nov 9, 2007
09:15 ET CEL-SCI CORPORATION ANNOUNCES ADOPTION OF SHAREHOLDER RIGHTS PLAN

  Oct 30, 2007
09:05 ET CEL-SCI TO PRESENT AT RODMAN & RENSHAW 9TH ANNUAL HEALTHCARE CONFERENCE

  Oct 18, 2007
09:45 ET CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase

  Sep 19, 2007
09:30 ET CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein

  Sep 17, 2007
13:18 ET CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum

  Sep 10 , 2007
09:45 ET CEL-SCI Corporation Releases Letter to Shareholders

 

For additional and archived press releases, please click here.

 

 

News & Announcements

 

  

Webcasts